Format

Send to

Choose Destination
Diabetes Obes Metab. 2019 Jul 31. doi: 10.1111/dom.13842. [Epub ahead of print]

Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care.

Author information

1
Royal Derby Hospital, University Hospitals of Derby and Burton NHS FT, Derby, Derbyshire, UK.
2
King's College London, Weston Education Centre, Denmark Hill, London, UK.
3
Manchester Royal Infirmary, Oxford Road, Manchester, UK.
4
Sanofi, One Onslow Street, Guildford, UK.

Abstract

Type 1 diabetes mellitus (T1DM) remains one of the most challenging long-term conditions to manage. Despite robust evidence to demonstrate that near normoglycaemia minimizes (but does not completely eliminate) the risk of complications, its achievement has proved almost impossible to attain in a real-world setting. HbA1c to date has been used as the gold standard marker of glucose control and has been shown to reflect directly the risk of diabetes complications. However, it has been recognized that HbA1c is a crude marker of glucose control. Continuous glucose monitoring (CGM) provides the ability to measure and observe inter- and intraday glycaemic variability (GV), a more meaningful measure of glycaemic control, more relevant to daily living for those with T1DM. This paper reviews the relationship between GV and hypoglycaemia, and micro- and macrovascular complications. It also explores the impact of CGM, insulin pumps, closed-loop technologies, and newer insulins and adjunctive therapies on GV. Looking to the future, there is an argument that GV should become a key determinant of therapeutic success. Further studies are required to investigate the pathological and psychological benefits of reducing GV. This article is protected by copyright. All rights reserved.

KEYWORDS:

continuous glucose monitoring; glycaemic variability; type 1 diabetes mellitus

PMID:
31364268
DOI:
10.1111/dom.13842

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center